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Abstract
This study reports on 382 COVID-19 patients having undergone allogeneic (n= 236) or autologous (n= 146) hematopoietic
cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the
Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). The median age was 54.1 years (1.0–80.3) for
allogeneic, and 60.6 years (7.7–81.6) for autologous HCT patients. The median time from HCT to COVID-19 was
15.8 months (0.2–292.7) in allogeneic and 24.6 months (−0.9 to 350.3) in autologous recipients. 83.5% developed lower
respiratory tract disease and 22.5% were admitted to an ICU. Overall survival at 6 weeks from diagnosis was 77.9% and
72.1% in allogeneic and autologous recipients, respectively. Children had a survival of 93.4%. In multivariate analysis, older
age (p= 0.02), need for ICU (p < 0.0001) and moderate/high immunodeficiency index (p= 0.04) increased the risk while
better performance status (p= 0.001) decreased the risk for mortality. Other factors such as underlying diagnosis, time from
HCT, GVHD, or ongoing immunosuppression did not significantly impact overall survival. We conclude that HCT patients
are at high risk of developing LRTD, require admission to ICU, and have increased mortality in COVID-19.
Introduction
A novel coronavirus named SARS-CoV-2 emerged at the
end of 2019, and Coronavirus Disease 2019 (COVID-19)
started spreading worldwide [1–3]. The WHO classified
COVID-19 a pandemic on March 11, 2020, and as of
February 8, 2021, more than 106 million cases have been
verified worldwide, and more than 2,300,000 have died.
The EBMT has published recommendations regarding
polices and patient management [4]. There have been major
achievements in the management of COVID-19, but the
mortality remains high especially in patients with risk fac-
tors. Recently, extensive vaccination programs were initi-
ated to control transmission and to reduce morbidity and
mortality.
Hematopoietic cell transplant recipients (HCT) are prone
to develop severe infections with many viruses including
community-acquired respiratory viruses. To better under-
stand the impact of COVID-19, data collection began via
the Infectious Diseases Working Party of the EBMT and the
Spanish Hematopoietic Stem Cell Transplantation and Cell
Therapy Group (GETH). This manuscript presents the first
results of this collaborative effort.
This paper aimed to analyze the outcome of the first
wave of COVID-19 for patients registered in the study
and identified risk factors for lower respiratory tract dis-
ease (LRTD), the requirement for intensive care, and
mortality.
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This is an EBMT and GETH prospective survey merging
newly collected data with previous data existing in the
EBMT registry. All patients give informed consent for their
data to be included in the registry. Questions included the
symptoms at the time of diagnosis, potential risk factors for
development of pneumonia, the need for hospitalization,
intensive care, and outcome. Criteria for inclusion in the
study were that the patient should be PCR positive for
SARS-CoV-2 regardless of symptoms and have undergone
an allogeneic or autologous HCT at any time before the
diagnosis of COVID-19. A parallel data collection with
forms written in Spanish was used to collect data from
Spain by GETH. The two sets of case record forms (CRFs)
were almost identical with a few additional data fields used
in the Spanish forms. The Swedish central Ethical Board
(EPM 2020-01731) approved the study and other approvals
if required, were obtained according to national regulations.
For this analysis, patients diagnosed with SARS-CoV-2
infection at or before July 31, 2020, were included and
patients needed to have at least 6 weeks of follow-up. In
addition to the COVID-19 specific forms, the EBMT reg-
istry’s so-called Minimal Essential Data A (MED-A) was
used to extract previously submitted data regarding baseline
patient information, data regarding the underlying diag-




The resolution was defined as being alive with either clin-
ical or virologic resolution of COVID-19.
Lower respiratory tract disease
Since signs of LRTD are diverse and may develop over
time, several questions in the CRFs (i.e., oxygen support
requirements, pulmonary radiology findings, the results of
bronchoalveolar lavage, and the presence of clinical signs of
LRT such as shortness of breath, sibilants, rales, and
cough), were used to define LRTD. This assessment was
performed by two of the investigators (JLP and PL) and
used for the analysis.
Immunodeficiency scoring index (ISI)
This was calculated as previously described [5]. This score
was prepared for allogeneic HCT patients. Still for the
purpose of this study we used it also to analyze the complete
population as well as allogeneic and autologous separately.
Absolute lymphocyte count/C-reactive protein (ALC/CRP)
ratio was defined according to Lagunas-Rangel, 2020 [6].
Statistics
The main characteristics of patients were reported by
descriptive statistics. Median, minimum and maximum
values were used for continuous variables, while absolute
and percentage frequencies were used for categorical vari-
ables. The overall survival was estimated by using the
Kaplan–Meier methods, considering the death due to any
cause as an event and the time from COVID-19 infection to
the latest follow-up as survival time; the difference between
groups was tested by the log-rank test. Univariate and
multivariate risk factor analysis for overall survival were
performed with the Cox regression model. Univariate and
multivariate risk factor analyses for COVID-19 resolution
were performed with the cause-specific Cox regression
model, considering the resolution as the event of interest
and death due to any cause as a competing event. Univariate
and multivariate risk factor analyses for the requirement of
admission to an intensive care unit (ICU) and LRTD
development were performed with the logistic regression
model. Variables with a p value <0.2 at univariate analysis
were entered into the multivariate models and selected
according to a stepwise selection. A p value <0.05 was
considered statistically significant. All p values are two-
sided. All the analyses were performed using the statistical
software SAS v. 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Number of included patients
Three hundred eighty-two patients from 22 countries ful-
filled the criteria for inclusion. Two hundred thirty-six
patients had undergone allogeneic HCT and 146 auto-
logous. The median age in the entire cohort was 56.8 years
(min–max; 1.0–81.6). The corresponding median ages were
54.1 years (min–max; 1.0–80.3) for allogeneic and 60.6
years (7.7–81.6) for autologous HCT patients, respectively.
Thirty-two patients were children (<18 years of age; median
age 9.5 (1.0–16.9)). The median time from the most recent
HCT to diagnosis of COVID-19 was 17.9 months
(min–max; −0.9 to 350.3). The corresponding median
times were 15.8 months (min–max 0.2–292.7) in allogeneic
and 24.6 months (min–max; −0.9 to 350.3) in autologous
HCT recipients, respectively.
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Additional patient characteristics are shown in supple-
mentary Table 1. Details about donor type, conditioning,
stem cell source, and GVHD for the patients having
undergone allogeneic HSCT are shown in Table 1. 74.4%
of the patients were hospitalized during the COVID-19
episode.
Symptoms at diagnosis
Symptoms at diagnosis are summarized in Supplementary
Table 2. Thirty-four patients (8.9%) were reported to be
asymptomatic during SARS-CoV-2 infection. On the other
hand, 132/376 patients (35.1%) required supplemental
oxygen to keep saturation above 92% (data missing for six
patients). The median time to diagnosis from the start of
symptoms was 3 days (from thirty days before to 40 days
after the onset of symptoms).
Interventions
Different interventions were attempted in this patient cohort
reflecting the knowledge at the time of COVID-19. These
are summarized in Supplementary Table 3. Data is not
available regarding the use of anticoagulation as prophy-
laxis against or treatment of thromboembolic events.
Outcome of COVID-19
At the time of analysis, 107/377 (28.4%) patients had died
(66/231 allogeneic; 41/146 autologous). 69/236 (29.2%) of
males and 38/146 (26.0%) of females had died at time of
analysis (p= 0.48). The corresponding percentages in
allogeneic HCT recipients were 28.5% vs. 27.2% in males
and females, respectively. The median age of patients, who
died, was 62.2 years (4.5–80.3). Twelve patients died from
other causes than COVID-19 giving an attributable mor-
tality from COVID-19 of 25.2%. No follow-up had been
received for five patients. The median time from confirmed
infection to death was 18 days.
Thirty-two children were included in the study: 29 after
allogeneic and three after autologous HCT. Three of 32
children died: all after allogeneic HCT. The median time
from HCT to COVID-19 diagnosis in the children, who
died, was 2 months (2–15) while it was 4 months (−1 to 56)
in the children surviving COVID-19. Furthermore, there
was no difference in age between the children, who died (8
years; 4–12) or survived (10 years; 1–17).
Overall survival
The Kaplan–Meier overall survival curves for allogeneic
and autologous HCT patients are shown in Fig. 1. The
probabilities for survival at 6 weeks from diagnosis of
COVID-19 were 77.9% and 72.1% in allogeneic and
autologous HCT recipients, respectively. There was no
significant difference in survival between autologous and
allogeneic HCT patients (p= 0.8). Children had a higher
survival rate (p= 0.03; Fig. 2).
Table 1 Characteristics of patients having undergone allogeneic HCT.
N= 236
Stem cell source
BM (bone marrow) 37 (15.7)
PB (peripheral blood) 186 (78.8)
CB (cord blood) 4 (1.7)
Missing 9 (3.8)
HLA match
Matched family 78 (33.0)
Unrelated 111 (47.0)










aGvHD at time of COVID-19
no aGvHD/grade 1 132 (55.9)
grade 2–4 12 (5.1)
Chronic GvHD at time of COVID-19
No (never) 137 (58.0)







Fig. 1 Overall survival after diagnosis of COVID-19 infection in
allogeneic and autologous HCT recipients.
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In univariate analysis (Supplementary Table 4), risk
factors influencing overall survival in the total population
were age (p < 0.0001), performance status (p < 0.0001),
time from HCT to COVID-19 (p= 0.04), ISI intermediate
+ high vs. low (p= 0.0008), ANC (p= 0.018), and the
ALC/CRP ratio (p= 0.009). The age effect also remained
when only adults were included in the analysis. In addition,
the need for admission to ICU had a very strong impact on
overall survival (p < 0.0001). Looking more in detail on
time from HCT to COVID-19, the mortality in patients
developing COVID-19 the first 100 days after HCT was
35.8% vs. 26.8% (p=NS) in those developing COVID-19
beyond 100 days from HCT. The distribution of times from
HCT to diagnosis of COVID-19 and mortality is shown in
Table 2. The outcome in patients on or off immunosup-
pression split by time from HCT to COVID-19 is shown in
Supplemenary Fig. 1.
In multivariate analysis (Table 3), age (HR 1.21; 95% CI
1.03–1.43; p= 0.02) and higher ISI group (HR 1.84; 95%
CI 1.02–3.33; p= 0.04) increased the risk and better per-
formance status decreased the risk for fatal outcome (HR
0.83; 95% CI 0.74–0.93; p= 0.0001). These factors
remained significant also when adjusting for type of trans-
plantation and if admission to ICU was not included as a
variable in the analysis.
Factors significant in univariate analysis for overall sur-
vival in allogeneic HCT recipients were age (p= 0.0007),
performance status (p < 0.0001), need for admission to
ICU (p < 0.0001), and ISI group intermediate or high
(p= .0.0005). The age effect also remained when only
adults were included in the analysis. In multivariate analy-
sis, excluding ICU admission age (HR 1.28; 95% CI
1.05–1.55; p= 0.01) and performance status (HR 0.79;
95% CI 0.68–0.92; p= 0.002) had a significant impact on
overall survival. Only age (HR 1.29; 95% CI 1.05–1.58; p
= 0.01) remained significant when ICU (HR 4.42; 95% CI
2.25–8.65; p < 0.0001) was included in the model.
The factors significant in univariate analysis for overall
survival in autologous HCT patients were age (p= 0.01),
performance status (p= 0.02), and admission to ICU (p=
0.002). The age effect also remained when only adults were
included in the analysis. The only factor impacting overall
survival in multivariate analysis (Table 3) was higher age
(HR 2.26; 95% CI 1.22–4.20; p= 0.01).
Resolution
Of the patients reported to be alive, the median follow-up
was 47 days (5–250 days). One hundred eighty-six (64.3%)
patients (117 allogeneic; 69 autologous), excluding patients
who died from COVID-19, had virologic resolution of the
COVID-19 infection. The median time to virologic resolu-
tion was 24 days with the longest being 210 days. In
addition, 58 patients (37 allogeneic and 21 autologous) had
clinical resolution but had not been tested again with PCR.
25 patients were alive but known to be still COVID-19
positive (13 allogeneic; 12 autologous). We had no infor-
mation on five patients.
Factors impacting on resolution were in univariate ana-
lysis high-performance status (1.14 (1.02–1.27), p= 0.02),
moderate/high ISI group (0.73 (0.54–0.99), p= 0.04), lung
pathology (0.70 (0.48–1.01), p= 0.05), the underlying
diagnosis (NHL/Hodgkin/CLL vs. AML/ALL 0.65
(0.45–0.94), p= 0.02), and ALC ≥ 200 (1.64 (1.02–2.66),
p= 0.04; supplementary table 4). Besides, ICU admission
impacted on resolution (0.47 (0.32–0.70), p= 0.0002). In
multivariate analysis (Table 3), only the underlying disease
had a significant impact if ICU was not in the model, while
ICU admission and performance status were significant in a
model including ICU care.
In allogeneic HCT patients the factors influencing reso-
lution in univariate analysis were high-performance status
(1.24 (1.08–1.43), p= 0.003), ISI group moderate/high
(0.58 (0.39–0.84), p= 0.004), presence of GVHD (0.70
(0.50–0.99), p= 0.04), ALC ≥ 200 (2.03 (1.08–3.83), p=
0.03), need for ICU care (0.42 (0.25–0.70), p= 0.001), and
ongoing immunosuppressive treatment (0.57 (0.39–0.83),
p= 0.003; Supplementary Table 4). In multivariate analysis
the underlying diagnosis excluding the ICU variable, time
from HCT to COVID-19, the diagnosis, and ISI group
Fig. 2 Survival after diagnosis of COVID-19 in adults and children.
Table 2 Impact of time between HCT and diagnosis of COVID-19 on
mortality.
Total Allo Auto
Time after HCT Patients Deaths Patients Deaths Patients Deaths
0–100 67 24 44 17 23 7
100-6 mm 31 9 22 7 9 2
6mm-1y 56 19 37 12 19 7
12–18 mm 36 12 24 10 12 2
18mm-2y 26 6 18 2 8 4
≥2yy 161 37 89 18 72 19
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influenced the time to resolution while with ICU variable
included, ICU admission, performance status and country-
influenced resolution (Table 3).
Lower respiratory tract disease (LRTD)
308/369 (83.5%) patients developed LRTD (data missing
for 13 patients). Results of the univariate analyses are
shown in Supplementary Table 1. In multivariate analysis
(Table 3), increasing age (HR 1.41; 95% CI 1.17–1.69; p=
0.0002) and lymphocyte/CRP ratio (HR 0.32; 95% CI
0.13–0.80; p= 0.015) were significant in the total popula-
tion. In allogeneic HCT patients, age (HR 1.39; 95% CI
1.14–1.71; p= 0.002) and ongoing immunosuppression
(HR 2.78; 95% CI 1.02–7.60; p= 0.046) increased the risk
for LRTD while in autologous patients age (HR 1.72; 95%
1.07–2.74; p= 0.02) and longer time after HCT (HR 3.93;
95% 1.38–11.22; p= 0.01) had a significant impact on the
risk for LRTD.
Requirement of admission to an intensive care unit
80/356 (22.5%) patients received ICU care (data missing for
26 patients). The median time from diagnosis of COVID-19
to admission to ICU among 69 patients for whom we have
information (data missing on 11 patients) was five days (−5
to 35). The median time from diagnosis to ICU care was
seven days in allogeneic and four days in autologous HCT
patients. 38/69 patients died within six weeks from the day
of ICU admission.
Patients diagnosed with COVID-19 later than one year
after HCT had in univariate analysis (Supplementary
table 4) a lower risk of admission to an ICU (p= 0.02).
Other factors are shown in Supplementary Table 1. In
multivariate analysis, moderate/high ISI group (OR 2.59;
95% CI 1.33–5.05; p= 0.005) and country (p= 0.007)
were significant factors for ICU admission. If ISI was not
included in the model, the ALC/CRP ratio was significant
together with country (Table 3).
In multivariate analysis including only allogeneic HCT
recipients, only ongoing immunosuppression increased the
risk for ICU admission (HR 3.69; 95% CI 1.06–12.87; p=
0.04). No factor had significant impact on the risk for
admission to ICU among autologous patients in multivariate
analysis.
Discussion
The emergence of SARS-CoV-2 and COVID-19 has had a
very strong impact on transplant centers fearing for the
outcome of this disease in a population known to be vul-
nerable to viral infections in general and to community-
acquired respiratory viruses [7–12]. Here, we present a
series of 382 patients from 22 countries collected pro-
spectively through the EBMT registry and in close colla-
boration with the Spanish GETH, which is the largest
patient cohort with COVID-19 after HCT presented to date.
Overall, COVID-19 was a severe complication in HCT
recipients with an attributable mortality of 25%. This can be
compared to the case fatality rates during the 1st wave in
some European countries and the USA, 4–10%
(https://www.worldometers.info/coronavirus/). The median
age in our population of patients having undergone allo-
geneic HCT was 54.1 years and 60.6 years in patients
having undergone autologous HCT, with the majority being
below 70 years of age. We found a 6-week probability of
survival of 77.9% and 72.1% in allogeneic and autologous
HCT recipients, respectively. The mortality rates in Sweden
were 4.6%, 1.1%, and 0.1% in patients 60–69, 50–59, and
<50 years of age, respectively (www.folkha
lsomyndigheten.se/ August 13, 2020). This date corre-
sponds approximately with the cut-off date for inclusion in
this patient series. Thus, the mortality in our cohort is much
higher than in the general population. In the general
population, mortality seems to be lower in the second wave
and it remains to be seen if that is the case in HCT recipients
as well.
The CIBMTR published results on 314 patients with
COVID-19 [13]. Their 30-day survival after diagnosis of
COVID-19 was 68% among allogeneic HCT recipients and
67% among autologous HCT recipients. They found age
over 50, male sex, and time from HCT to COVID-19
diagnosis of less than a year to be significant risk factors for
mortality among allogeneic recipients. In contrast, only
diagnosis of lymphoma had an impact on survival among
autologous recipients. They did not report the impact per-
formance status at COVID-19 as a potential risk factor,
which was highly significant in our series. On the other
hand, we could not find any impact of sex on mortality.
They reported only 10.9% mortality among female allo-
geneic HCT recipients compared to 27.2% in our series.
The corresponding percentages in males were 33.7% vs.
28.5% in the CIBMTR and our series, respectively. These
differences are unexplained.
In another smaller series, Shah et al. reported a 30-day
survival of 78% in 72 HCT patients and 5 CAR T-cell-
treated patients [14]. Their median time from HCT to
COVID-19 diagnosis was slightly more than 2 years com-
pared to 18 months in our study. Although in our cohort, in
multivariate analysis, time from HCT to COVID-19 was not
an independent risk factor for poor outcome, the mortality
was 36% in patients diagnosed the first 100 days after HCT.
Coll et al. reported in a series, which included solid organ
transplant patients [15], a mortality of 20% and 24% among
56 allogeneic HCT and 29 autologous HCT patients,
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respectively. In this study, the time median from HCT to
COVID-19 was similar as in our study (15 months in
allogeneic and 18 months in autologous HCT recipients).
Other studies of HCT patients have reported similar out-
comes [14–22].
Cancer patients are more vulnerable to develop severe
COVID-19. In a study of 107 cancer patients in China with
a median age of 66 years, the mortality was 21.5% [3],
which is comparable to our patient cohort. However, our
cohort’s median age was a decade younger. Scarfò et al
reported high mortality in patients with CLL with a median
age of 72 years and found that the risk for severe COVID-
19 disease was associated with higher age (>65 years). Still,
neither older age nor comorbidities influenced mortality
[23]. In a series of solid organ transplanted patients, Kates
et al. reported a similar mortality of 20.5% at 28 days after
diagnosis of infection [24].
Other indicators of the severity of COVID-19 in our
patients were a rate of LRTD of 83.5% and a rate of
admission to ICU of 22.5%. These figures can be compared
to the experience with the H1N1 “Swine flu” pandemic in
which the corresponding numbers were 32.5% and 11.5%
for LRTD development and need of intensive care,
respectively [25]. The figures can also be compared to the
rates of ICU admission in Sweden during the 1st wave,
which is a country where there was no lack of ICU beds
during the pandemic. Given that the median age of the HCT
cohort was 56 years the best corresponding rates of ICU
admission in Sweden were 8.9% in patients 60–69 years,
4.3% in those 50–59 years, and 1.1% in patients below 50
years of age (www.folkhalsomyndigheten.se/ August 13,
2020). Nine percent of our cases were asymptomatic, but it
is likely that our numbers reflect a selection bias since not
all patients having undergone HCT and infected with
SARS-CoV-2 have sought medical care, especially those
with no or mild symptoms or those being a long time after
HCT and without complications from the transplantation.
Additional studies of serological evidence of COVID-19
might elucidate this question.
We calculated indices to see if any of those helped pre-
dict outcome. ISI impacted on survival and ICU admission
in the total population. It also impacted on resolution and
ICU admission in patients having undergone allogeneic
HCT but had no added value in autologous patients. This
index was developed for allogeneic HCT with RSV infec-
tions. This report supports that it is also useful for COVID-
19. The ALC/CRP ratio also had a significant impact on the
risk for LRTD and need for ICU admission but not for
survival. Both these are easy to calculate and might be
helpful in the clinical assessment of SARS-CoV-2 patients.
Some of our findings were expected such as that overall
survival was influenced by patient age and performance
status. Age has been an important factor in most reports on
COVID-19 in the general population [26–28]. Poor per-
formance status is usually due to comorbidities such as
extensive GVHD, but in this cohort, we were unable to find
a correlation of specific comorbidities with the HCT out-
comes. Kates et al. also found age and comorbid conditions
as drivers of mortality in solid organ transplant recipients
[24]. Children seemed to do better. We present results of
COVID-19 in 32 children after HCT of whom 29 survived.
This also fits with what has been reported in the general
population [29], and also with a report of eight HCT chil-
dren with COVID-19 of whom seven survived [17].
More surprising was that the type of transplantation did
not impact on overall survival. Allogeneic HCT patients are
much more likely to develop severe complications from
other respiratory viruses such as RSV and parainfluenza
viruses [30–32]. However, studies reported no difference
between risk for mortality in autologous and allogeneic
HCT patients with influenza such as during the H1N1
“Swine flu” pandemic [25, 33].
It was also surprising that the time from HCT did not
impact overall survival and neither did ongoing immuno-
suppression, presence of GVHD, preexisting pulmonary
morbidity, or the granulocyte or lymphocyte count. Several
of these factors have been shown to be of importance for
outcome in other respiratory virus infections
[5, 7, 12, 34, 35]. Contracting SARS-CoV-2 infection later
than a year after allogeneic HCT was associated with a
higher rate of resolution. Furthermore, when using the ISI,
which includes several of these factors to create an assess-
ment of the total immunodeficient status [5], patients with a
moderate or high index had increased mortality if ICU
admission was not included as a variable. Furthermore, high
ISI increased the patient’s risk to require ICU care and
negatively impacted on time to resolution among allogeneic
HCT recipients. In addition, ongoing immunosuppressive
therapy impacted the risk for LRTD and the need for ICU
admission in allogeneic HCT recipients. An essential factor
for the morbidity in COVID-19 is immune system activa-
tion including effects on the T-cell responses [36–38]. It
could be that patients on immunosuppression might be
partly protected against this aspect of COVID-19 patho-
genesis. In contrast, immunosuppression could prolong
viral excretion by suppressing viral clearance either by the
production of specific antibodies or by suppressing the T
cell or NK cell functions. These possibilities will have to be
investigated in a larger cohort.
It should be recognized that this study included patients
developing COVID-19 during the 1st wave. Although we
have information on used therapeutic interventions, the data
do not allow detailed analysis of the potential effects of
antiviral drugs or anti-inflammatory agents due to the het-
erogeneity of the population, the non-controlled nature of
the study, and the variation in different interventions
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making it too difficult, even with the size of this study, to
get reliable estimates of potential therapeutic effects.
We can conclude from this study that COVID-19 resul-
ted in high rates of morbidity and mortality supporting that
preventing infections in these patients is of uttermost
importance. Furthermore, even in a high-risk cohort such as
HCT recipients, there are groups at higher and lower risk for
poor outcome. The most critical factors are older age and
poor performance status presumably due to comorbidities
although we could not pinpoint important individual
comorbidities. Hopefully, this knowledge can help patients
and transplant centers to design interventions and protective
measures including vaccines to decrease this risk in this
highly vulnerable patient group.
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